Objective: T-cell lymphoma invasion and metastasis 1 (Tiam1) specifically activates Rho-like GTPases (e.g. Rac1) and Tiam1 -Rac1 pathway affects the migration and invasion of many tumors, such as nasopharyngeal carcinoma, breast cancer and retinoblastoma. However, no studies have yet comprehensively examined the involvement of Tiam1 -Rac1 pathway in hepatocellular carcinoma. In this study, we examined the relationship of the up-regulation of Tiam1 and Rac1 with clinicopathological features in patients with hepatocellular carcinoma. Methods: Expression of Tiam1 and Rac1 was assessed in 242 hepatocellular carcinoma tissues and their adjacent normal hepatic tissues by performing immunohistochemistry and was gauged regarding stage, grade and survival. Results: Immunohistochemistry showed that patients with a high clinical stage hepatocellular carcinoma (III -IV) and a-fetoprotein levels had a higher tendency to express Tiam1 and Rac1 on tumor cells than the patients with low pathologic grade hepatocellular carcinoma (I -II) (P ¼ 0.008 and 0.01, respectively) and low a-fetoprotein levels (P ¼ 0.006 and 0.002, respectively). In addition, Tiam1 and Rac1 up-regulation was also significantly associated with vascular invasion status (both P ¼ 0.02), intrahepatic metastasis status (P ¼ 0.009 and 0.01, respectively) and histological differentiation (P ¼ 0.008 and 0.009, respectively) of patients with hepatocellular carcinoma. Moreover, post-operative survival analysis indicated that hepatocellular carcinoma patients with strong Tiam1 (P ¼ 0.01) and Rac1 (P ¼ 0.02) expression had shorter disease-specific survival than those with weak expression. Multivariate analysis also showed that Tiam1 and Rac1 overexpression could be two predictors of poor prognosis (P ¼ 0.02 and 0.03, respectively). Conclusions: The current study demonstrated for the first time that the Tiam1 -Rac1 pathway may play a critical role in tumor progression of hepatocellular carcinoma. The expression of Tiam1 and Rac1 can be considered as the two useful indicators for predicting the prognosis of hepatocellular carcinoma.
INTRODUCTION
Hepatocellular carcinoma (HCC), the fifth most common malignancy worldwide and the third most common cause of cancer-related deaths (1) , has an increasing incidence in recent years (2) . It is characterized by difficult diagnosis, high malignancy and early metastasis. The majority of HCC patients have associated cirrhosis and impaired liver function, making the treatment of HCC more difficult than that of many other cancers. Surgery, including transplantation, remains the only potential curative modality for HCC (3) . Prognosis of HCC remains unsatisfactory even after surgical resection and liver transplantation. Consequently, a key point for preventing and curing HCC is to study the molecular mechanism of invasion and metastasis of tumor cells and to identify a method to control early invasion and metastasis.
Rho proteins, including Rac, Cdc42 and Rho, are essential regulators of various cellular processes such as actin # The Author (2010). Published by Oxford University Press. All rights reserved.
Jpn J Clin Oncol 2010;40 (11) 1053-1059 doi:10.1093/jjco/hyq086 Advance Access Publication 3 June 2010 cytoskeleton reorganization, mitogenesis, activation of kinase cascades, transcriptional activation and stimulation of DNA synthesis (4, 5) . It is assumed that the activity status of Rho proteins undergoes time-and spatial-dependent fluctuations during the different steps involved in tumor progression and metastasis (6) . As the activity status of Rho GTPases is regulated by Rho regulatory factors including guanine exchange factors (GEFs) which are known to be oncogenic, changes in the expression level of these factors may also change with malignancy. T-cell lymphoma invasion and metastasis 1 (Tiam1) that belongs to Dbl family proteins is a Rac-specific GEF involved in the activation of small GTPase proteins (Rac, Cdc42 and Rho). It has been identified as an invasion-and metastasis-inducing gene in a murine T-lymphoma cell line (7, 8) , and it activates the Rho-like GTPase Rac1. Tiam1 -Rac1 signaling affects the migration, invasion and metastasis of many tumor cells. For instance, N-terminal truncation of the Tiam1 protein could activate its oncogenic potential in NIH3T3 cells (9); Qiu et al. (10) have found that Rac1 is also essential for Ras-induced transformation; Tiam1-deficient mice are resistant to the growth of Ras-induced skin tumors; strong Tiam1 overexpression in prostate cancer correlates with aggressive disease and is an independent prognostic indicator of disease recurrence (11) .
However, the involvement of Tiam1 -Rac1 pathway in HCC has not yet been thoroughly investigated. Therefore, in this study, we investigated tissue specimens from patients with HCC for the expression patterns of Tiam1 and Rac1 by immunohistochemical staining. The aim of this study was to identify whether the overexpression of Tiam1 and Rac1 is interrelated to HCC and to define the extent of their association with the progression of this disease. In addition, we hoped to determine whether Tiam1 and Rac1 expression could serve as prognostic factors for HCC.
PATIENTS AND METHODS

PATIENTS AND TISSUE SAMPLES
The study was approved by the Research Ethics Committee of Medical School of Xi'an Jiaotong University, Shanxi, China. Informed consent was obtained from all of the patients. All specimens were handled and made anonymous according to the ethical and legal standards.
In this study, fresh HCC samples and their adjacent normal hepatic tissues were obtained from 242 patients (186 men and 56 women, with a mean age of 65. (Table 1) . Follow-up data after surgery were obtained from all patients, with a median follow-up period of 53 months.
IMMUNOHISTOCHEMISTRY ANALYSIS
The specimens were fixed in 10% neutral-buffered formalin and subsequently embedded in paraffin. The paraffinembedded tissues were cut at 3 mm and stained following being dried on ProbeOn Plus (Fisher Scientific International, Hampton, NH, USA). Staining was done using avidin -biotin complex with a microprobe manual stainer (Fisher Scientific International). The slide to which a paraffin section was attached went through deparaffinization and hydration and was then treated with a solution of peroxidase-blocking reagent (Dako, Glostrup, Denmark) to exhaust endogenous peroxidase activity. It was put in citric acid solution and heated for 10 min in a microwave and then left at room temperature for 20 min to expose antigen hidden inside the tissue due to formalin fixation, and the process was repeated three times. To inhibit non-specific antigen-antibody reactions possible in immunohistochemical staining, reaction was done using a protein blocker (Research Genetics, Huntsville, AL, USA) for 5 min and the slide was washed thoroughly with water. The slides were incubated overnight with the primary antibodies against Tiam1 (1: 125, SC-872, Santa Cruz Biotechnologies, Santa Cruz, CA, USA) and Rac1 (1: 100, ab33186, Abcam, Cambridge, MA, USA) at 48C. The 
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Prognostic value of Tiam1 and Rac1 in HCC specificity of the two antibodies has been validated by the study of Qi et al. (12) . Secondary antibodies for the detection of primary antibodies were reacted for 10 min using anti-mouse IgG (Sigma, St Louis, MO, USA) to which biotin was attached, and then washed with buffer solution and reacted with horseradish peroxidase for 10 min. It was washed thoroughly with buffer solution; chromogen AEC (3-amino-9-ethylcarvazole; Zymed, San Francisco, CA, USA) was then applied and reddish brown response was examined. After hematoxylin contrast staining, the slide was enclosed with Universal Mount (Research Genetics) and examined. In each immunohistochemistry run, negative controls were carried out by omitting the primary antibody, whereas Tiam1 and Rac1 overexpression confirmed by western blotting was used as positive controls. Following a hematoxylin counterstaining, immunostaining was scored by two independent experienced pathologists, who were blinded to the clinicopathological parameters and clinical outcomes of the patients. The scores of the two pathologists were compared and any discrepant scores were trained through re-examining the stainings by both pathologists to achieve a consensus score. Immunostaining of Tiam1 and Rac1 were interpreted using a previously described scoring method (12) . Immunoreactivity was scored into three groups according to the percentage of cytoplasmic (for Tiam1) or nuclear (for Rac1) staining of the positively stained tumor cells. The numbers of positively staining cells were scored as 0% (0), 1-33% (1) and .34 (2).
STATISTICAL ANALYSIS
SPSS13.0 software for Windows (SPSS Inc., USA) and SAS 9.1 (SAS Institute, NC, USA) was used for statistical analysis. Continuous variables were expressed as X + s. Statistical analyses were performed with Fisher's exact test for any 2 Â 2 tables, Pearson's x 2 test for non-2 Â 2 tables, Spearman's correlation for evaluation of the association between Tiam1 and Rac1 protein expression, the KaplanMeier method for the question of survival, the Chiquest trend test for ordinal datum and Cox's regression analysis for the multivariate analysis. The P values of ,0.05 were considered to be statistically significant.
RESULTS
IMMUNOHISTOCHEMICAL EXPRESSION AND LOCALIZATION OF TIAM1 AND RAC1
Positive staining for Tiam1 was mainly observed in the cytoplasm (Fig. 1A ) and for Rac1 (Fig. 1B) was in the nuclei of cancer cells. Of the 242 HCC specimens analyzed, 18 (7.4%) had negative staining for Tiam1, 68 (28.1%) tumors had Tiam1 staining score as 1 and 156 (64.5%) had Tiam1 staining score as 2. Immunohistochemical analysis for Rac1 was also performed on serial sections from the same tumors. In 32 of 242 (13.2%) specimens, Rac1 staining was negative, in 58 (24.0%) specimens its staining score was 1 and 152 (62.8%) had Rac1 staining score as 2. When the high expression level was defined as more than 34% of the tumor cells with positive staining, the high expression rates of Tiam1 and Rac1 were 64.5% (156/242) and 62.8% (152/ 242), respectively. In addition, when the expression levels of Tiam1 and Rac1 were compared with the adjacent normal hepatic tissues, the differences were found to be significant (Tiam1 and Table 2 lists the correlation of Tiam1 and Rac1 expression patterns with the clinicopathological parameters of patients with HCC. In patients with vascular invasion and intrahepatic metastasis, strong expression (staining score as 2) of Tiam1 and Rac1 was noted in 75.6% and 68.2% of patients, respectively, whereas 58.7% and 59.7% of patients without vascular invasion (both P ¼ 0.02) and intrahepatic metastasis (P ¼ 0.009 for Tiam1 and 0.01 for Rac1) showed strong expression of two proteins (Table 2 ). In addition, in regard to the well-known pathological prognostic factors such as histological differentiation degree, a-fetoprotein (AFP) levels and clinical stage, statistically significant correlation with Tiam1 and Rac1 expression patterns was noted. The Stage III -IV group had the higher rate of strong expression (for Tiam1 and Rac1: both n ¼ 96, 78.7%) and the lower rate of weak expression in Tiam1 and Rac1 (for Tiam1: n ¼ 26, 21.3%; for Rac1: n ¼ 22, 18.0%) than the Stage I -II group did. These findings suggested that the number of Tiam1-and Rac1-positive cells was significantly increased in HCC tissues with the advanced clinical stage (for Tiam1: P ¼ 0.008; for Rac1: P ¼ 0.01). With the same trend, the Tiam1 and Rac1 expression in HCC tissues with poor histological differentiation was also significantly stronger than those with well and moderate differentiation (for Tiam1: P ¼ 0.008; for Rac1: P ¼ 0.009). Moreover, the HCC patients with high AFP levels had a higher tendency to express Tiam1 and Rac1 on tumor cells than those with low AFP levels (for Tiam1: P ¼ 0.006; for Rac1: 0.002). However, the strong (staining score as 2) or weak (staining score as 1) Tiam1 and Rac1 expression ratios did not statistically correlate with the patients' gender and tumor size ( Table 2) .
PROGNOSTIC VALUES OF TIAM1 AND RAC1 EXPRESSION IN HCCS
Using the Kaplan -Meier method and log-rank test, HCC tissues with stronger expression of Tiam1 and Rac1 were correlated to shorter recurrence-free survival ( Fig. 2A and  C ; log-rank value 21.0 and 21.3; both P ¼ 0.01, respectively) or disease-specific survival of patients ( Fig. 2B and D ; log-rank value 25.2 and 25.8; both P ¼ 0.03, respectively). The factors relating to the patients' prognosis were evaluated by univariate and multivariate analyses ( Table 3 ). The univariate analysis showed that vascular invasion (P ¼ 0.03), intrahepatic metastasis (P ¼ 0.01), histological differentiation degree (P ¼ 0.008), AFP levels of patients (P ¼ 0.01), tumor stage (P ¼ 0.002), Tiam1 expression (P ¼ 0.01) and Rac1 expression (P ¼ 0.02) were significantly related to post-operative survival. In the multivariate analysis, intrahepatic metastasis (P ¼ 0.02), histological differentiation degree (P ¼ 0.01), tumor stage (P ¼ 0.02), Tiam1 expression (P ¼ 0.02) and Rac1 expression (P ¼ 0.03) were the independent prognostic factors for HCC patients.
DISCUSSION
The results from our study revealed a significant increase in the expression of Tiam1 and Rac1 in HCC tissues than the corresponding adjacent hepatic tissues; the expression levels of the two proteins in the former was 92.6% and 52.5%, respectively, and those in the later were 16.5% and 14.9%, respectively. These results indicated that these proteins play important roles in hepatocarcinogenesis. The mechanisms on a molecular level and genes associated with the invasion and metastasis of HCC cells are still poorly understood. Several novel biological markers involved in invasion and metastasis have been identified in recent studies. Although activating mutations of the Rho GTPases are uncommon, elevated expression at the mRNA and protein level has been demonstrated and correlated with tumor stage or enhanced metastasis in tumors such as breast cancer, melanomas and germ cell tumors (13 -15) . Rac1 is a member of the Rho-family of GTPases, which are important regulators of actin-cytoskeleton-dependent processes such as morphogenesis, adhesion and migration. Rho-family proteins are involved in malignant transformation and tumor invasion, as shown for T-lymphoma, carcinoma, hepatoma and melanoma cells (16 -18) . Tiam1 is one important regulator of Rho GTPase functions in tumor cells. The overexpression of Tiam1 and Rac1 in tumors has been fully reported in previous studies. Through Rac activation, Tiam1 induces T-cell 
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Prognostic value of Tiam1 and Rac1 in HCC lymphoma, B cell lymphoma, melanoma, fibrosarcoma, breast cancer, lung cancer, nasopharyngeal carcinoma, ovarian cancer, bladder cancer and pancreatic cancer invasion and metastasis (19 -22) . Moreover, the Rho GTPases RhoA and Rac1 are also necessary for the formation and maintenance of cadherin-dependent cell -cell contacts. RhoA and Rac1 activities in the disassembly of cell -cell contacts for, for example, Tiam1 activation of Rac promoted migration of Madin -Darby canine kidney cells on collagen substrate but inhibited migration on a fibronectin or laminin substrate (23) (24) (25) .
In the current study, we found that the up-regulation of Tiam1 and Rac1 in HCC tissues was correlated with advanced clinical stage, poor histological differentiation degree, high AFP levels, the presentation of vascular invasion and intrahepatic metastasis. When assessing the immunohistochemical results from HCC nodules in comparison with the non-cancerous tissues, post-operative survival analysis indicated that HCC patients with strong Tiam1 and Rac1 expression had a lower disease-specific survival rate than those with weak and negative expression. Furthermore, in multivariate analysis, Tiam1 and Rac1 expression showed a statistically significant correlation with disease-specific survival. These results indicated that enhanced expression of Tiam1 and Rac1 might promote the malignant potential of HCC. Similar to disease-specific survival, groups with strong Tiam1 and Rac1 expression showed a lower recurrence-free survival between strong and weak expression groups and the difference was statistically significant. Vascular invasion and AFP level had a significant P value on univariate analysis; however, these two factors did not appear as a risk factor on multivariate analysis. One reason may be the small number of patients in this series. In addition, vascular invasion is the result of cancer progression and is often recognized in large tumors rather than small HCCs.
According to the results mentioned above, the Tiam1 -Rac1 signal pathway may serve as a new therapeutic target of HCC for the following reasons. The first is that the In conclusion, the current study demonstrated for the first time that the Tiam1 -Rac1 pathway may play a critical role in tumor progression of HCC. The expression of Tiam1 and Rac1 can be considered as the two useful indicators for predicting the prognosis of HCC and thus provides further impetus for exploiting this pathway as a novel target for the treatment of HCC.
